Fibromyalgia on a Decade-Old Tramadol Regimen: Taper Toward Guideline, or Maintain What Works?
The fibromyalgia guideline most specific to her diagnosis does not tell anyone to stop tramadol — it mildly endorses it. The opioid-stewardship guidance governing chronic pain generally points the other way, and neither was written with a patient eleven years into a fixed dose in view.
Bettina H., a 58-year-old woman who has lived alone in the same house since her divorce fourteen years ago and does all her own shopping and errands, was diagnosed with fibromyalgia thirteen years ago and started on tramadol 50mg twice daily two years after that, prescribed by a physician no longer at this practice and a year before the earliest of the guidance documents now being cited against it existed. She has held the same 100mg total daily dose for eleven years — a flat dose curve with no escalation across that entire span, which is the pattern least consistent with the tolerance a mu-agonist maintained this long would ordinarily be expected to produce. She has never requested an early refill, has no history of substance use, and describes the tramadol as "the only thing that lets me get through the grocery store without needing to sit down." Her function has been stable across that entire span — she still does her own housework, drives herself to appointments, and has never had a fall or a cognitive complaint attributable to the medication. She was not, until this visit, aware that any guidance existed on the drug she has been taking for a decade.
That guidance is more divided than a summary of it suggests, and it divides on which opioid is meant. Macfarlane and colleagues' 2017 EULAR fibromyalgia recommendations advise against strong opioids outright — but they place tramadol in a separate category, grading it "weak for," the same tier they assign pregabalin and duloxetine. The guideline written specifically for her diagnosis does not tell her physician to stop the drug she is on. What it does not do is describe her: the tramadol evidence EULAR graded came from trials running weeks, none following anyone held at a fixed dose for eleven years, so she sits outside that recommendation's studied population in the one direction it is silent about. Pulling the other way is the CDC's 2022 clinical practice guideline, which replaced the 2016 version that was still years from publication when her prescription began; it addresses chronic pain generally rather than fibromyalgia, prefers nonopioid therapy, and carries the concern that matters most mechanistically here — opioid-induced hyperalgesia, a sustained-exposure sensitization that would compound rather than treat a condition already defined by central sensitization. That same 2022 guideline, though, warns explicitly against abruptly tapering patients on long-term opioid therapy, as does the 2019 HHS tapering guidance written after guideline-driven tapers produced worsened pain, psychological distress, and patients seeking opioids elsewhere. Nothing in front of the team today actually recommends what is being proposed, in either direction.
Annual medication review, eleven years into the same regimen
I want to state the guideline position precisely, because it gets summarized wrong in both directions. EULAR does not discourage tramadol — Macfarlane and colleagues graded it "weak for" in 2017, and I'm not going to pretend otherwise. But "weak for" is the tier you assign when the trial data are thin and short, and what sits underneath that grade is a handful of studies running weeks. Nobody graded eleven years. Against that we have opioid-induced hyperalgesia, a real and mechanistically distinct concern in a condition already defined by central sensitization, and a 2022 CDC guideline that prefers nonopioid therapy for chronic pain generally. A permission built on twelve-week data is not an endorsement of a decade.
I don't dispute the guideline, and I'm not arguing we'd start tramadol for her today if she walked in treatment-naive.
But watch what just happened to the argument. You conceded EULAR grades tramadol "weak for," then reasoned from the CDC's general chronic-pain document instead — and that one doesn't address fibromyalgia at all. The guideline that actually covers her diagnosis points the other way. Worse for the taper case: the same 2022 CDC guidance you're invoking warns explicitly against abrupt tapering of long-term opioid patients, as does the 2019 HHS guidance written after guideline-driven tapers produced worsened pain, psychological distress, and patients seeking opioids elsewhere. You don't get to take the stewardship half of that document and leave the tapering half behind.
Then notice what the two of you are actually disagreeing about, because it is no longer what the guidelines say — you now agree on that. It is whether a "weak for" graded on twelve-week data stretches across eleven years, and neither document answers it, because neither studied it. There is one claim both share, though: that a non-opioid agent can manage fibromyalgia at least as well. That claim has never been tested in her, since nothing was tried before tramadol was started.
So I'd add duloxetine alongside her current tramadol, unchanged for now, and reassess at three months whether it is doing real, independent work. If it is, a taper becomes a decision made from evidence about her rather than an extrapolation neither guideline licenses. If it isn't, we are no worse off, and we haven't repeated the rapid-taper harm both the HHS and CDC documents now warn against.
Duloxetine started alongside her unchanged tramadol regimen, with reassessment at three months to determine whether it is contributing independent benefit before any taper decision is made.
Not agreed, and explicitly carried forward rather than resolved today: what happens if duloxetine shows only modest benefit at three months, neither a clear win nor a clear failure.
The pain medicine specialist would treat any real duloxetine benefit, however modest, as grounds to begin a slow taper trial, on the view that a "weak for" graded on short-term data cannot justify indefinite continuation once an alternative shows any independent effect.
The primary care physician would want a materially larger benefit before disturbing eleven years of documented functional stability, given that the diagnosis-specific guideline does not call for a taper and that tapering stable patients on ambiguous grounds carries its own documented harms.